º£½ÇÉçÇø

Award for achievements in antibody-drug conjugate development

Professor Ed Tate has received the Outstanding Academic Investigator Award at the 2026 World ADC Awards, announced in San Diego on 14 October. The award recognises his work on the development and commercialisation of N-myristoyltransferase (NMT) inhibitors as a new class of antibody–drug conjugate (ADC) payloads.

The research grew from the group’s studies of protein lipidation and its role in cancer, leading to the founding of Myricx Bio, now part of Novartis. By delivering NMT inhibitors to tumour cells through antibodies, this approach brings a distinct mechanism of action to ADC development.

Congratulations to Ed, and thanks to the students, postdocs, collaborators and Myricx colleagues whose contributions have made this journey possible. We also thank the World ADC judges for recognising the work.